Literature DB >> 17972504

Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole.

K Krauss1, C Bachmann, J T Hartmann, K Siegmann, K Sotlar, D Wallwiener, J Huober.   

Abstract

Low grade endometrial stromal sarcoma (LGESS) is a rare disease. LGESS usually expresses steroidal receptors and is regarded to be hormone-sensitive. Due to the rarity of the tumor, only few case series have been published so far. Here, we report the case of a 36-year-old woman who underwent an abdominal hysterectomy with bilateral salpingo-oophorectomy and adjuvant radiotherapy for a G1 LGESS in 1991. Twelve years later she presented to us with pelvic and peritoneal masses. The patient was treated with letrozole achieving a partial response which is lasting 39 months. Treatment is ongoing. Aromatase inhibitors represent an interesting treatment option for LGESS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17972504

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.

Authors:  Vonetta T Sylvestre; Charles J Dunton
Journal:  Horm Cancer       Date:  2010-01-29       Impact factor: 3.869

2.  Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.

Authors:  Hyewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

3.  Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study.

Authors:  Hiroyuki Yamazaki; Yukiharu Todo; Kenrokuro Mitsube; Hitoshi Hareyama; Chisa Shimada; Hidenori Kato; Katsushige Yamashiro
Journal:  J Gynecol Oncol       Date:  2015-04-16       Impact factor: 4.401

4.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.